Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients

Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with potential promise in this population. We describe PC...

Full description

Bibliographic Details
Main Authors:	Bruce A. Warden, PharmD, Tina Kaufman, PhD, PA-C, Jessica Minnier, PhD, P. Barton Duell, MD, Sergio Fazio, MD, PhD, Michael D. Shapiro, DO, MCR
Format:	Article
Language:	English
Published:	Elsevier 2020-03-01
Series:	JACC: Case Reports
Subjects:	dyslipidemia proprotein convertase subtilisin/kexin type 9 inhibitors solid organ transplantation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666084919306503

Internet

http://www.sciencedirect.com/science/article/pii/S2666084919306503

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients

Internet

Similar Items